The US Food and Drug Administration has approved Taihu for the treatment of rare bile duct cancer with a specific genetic signature

Taihu oncology drug for bile duct cancer is now agreed by the Food and Drug Administration, providing a new treatment option for patients with advanced disease. The regulatory decision makes Taihu the third approved product for such cancers driven by a specific genetic signature, but the drug company maintains that its cancer treatment has an … Read more

Rocket Pharma stocks cardiac gene therapies through $53 million acquisition of Renovacor

Gene therapy developer Rocket Pharmaceuticals is on track to gain FDA approval for its pioneering program, but it’s also interested in preserving its pipeline inventory. The company agreed to Acquisition of Renovacora biotechnology working to develop a gene therapy for a form of hereditary heart failure. According to financial terms announced Tuesday, the all-share transaction … Read more